Hospital
Johnston Memorial Hospital, INC
Johnston Memorial Hospital, INC was paid $35.91M by Medicaid between Jan 2018 and Dec 2024, across 365 billing codes. Its largest line is 99284, emergency room visit (serious) — 10% of everything it billed.
33Billing provider infoJOHNSTON MEMORIAL HOSPITAL, INC
ABINGDON, VA 24211
ABINGDON, VA 24211
33aNPI1104812684assigned 09/21/2005
33bProvider typePsychiatric Hospital Unit
28Total paid$35.91M
24GClaims991,907
24DCodes billed365
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Psychiatric Hospital Unit providers in Virginia
Rank by total paid#2 of 5
Median peer was paid$15K
This provider vs. median2,387×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official HILTON, SHANE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 135,988 | $3.14M | |
| 2019 | 174,612 | $5.00M | |
| 2020 | 135,214 | $4.76M | |
| 2021 | 134,503 | $4.72M | |
| 2022 | 137,403 | $5.64M | |
| 2023 | 159,677 | $7.02M | |
| 2024incomplete | 114,510 | $5.64M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 10% | 27,169 | 23,541 | $3.73M |
| 96361 | Intravenous infusion, hydration; each additional hour | 7.0% | 12,513 | 9,318 | $2.52M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.4% | 20,610 | 17,616 | $2.31M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.8% | 17,745 | 15,695 | $2.07M |
| 41899 | Unlisted procedure, dentoalveolar structures | 5.4% | 2,077 | 1,991 | $1.94M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 4.1% | 19,155 | 15,033 | $1.48M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 3.6% | 1,153 | 1,108 | $1.30M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.5% | 7,170 | 6,444 | $1.27M |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 2.4% | 3,305 | 3,028 | $866K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.4% | 18,731 | 4,695 | $856K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.2% | 5,413 | 4,703 | $806K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.9% | 1,897 | 1,737 | $668K |
353 more codes
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | 1.8% | 1,061 | $653K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 1.8% | 429 | $651K |
| 36415 | Collection of venous blood by venipuncture | 1.8% | 37,043 | $649K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 4,554 | $586K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 1.6% | 4,980 | $576K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 8,978 | $547K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.5% | 952 | $540K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.4% | 5,676 | $496K |
| 78815 | Positron emission tomography (PET) for limited area imaging | 1.3% | 813 | $458K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.3% | 2,661 | $457K |
| G0378 | Hospital observation service, per hour | 1.3% | 4,269 | $451K |
| 80053 | Comprehensive metabolic panel | 1.2% | 59,771 | $443K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.1% | 7,831 | $400K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | 1.1% | 795 | $392K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.0% | 5,110 | $366K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 8,705 | $355K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,388 | $344K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,665 | $325K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,714 | $316K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 767 | $275K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 1,666 | $264K |
| 43235 | <1% | 749 | $264K | |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,889 | $254K |
| 81001 | <1% | 22,646 | $241K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,831 | $234K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,666 | $231K |
| 95811 | <1% | 416 | $230K | |
| J3490 | Unclassified drugs | <1% | 8,426 | $224K |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 773 | $143K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,797 | $140K |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 835 | $138K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 340 | $135K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 236 | $130K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 2,916 | $117K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 14,858 | $106K |
| 93971 | <1% | 1,462 | $105K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 388 | $104K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 8,746 | $101K |
| 93017 | <1% | 1,146 | $98K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 5,460 | $96K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 790 | $96K |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 586 | $92K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 65,501 | $91K |
| C1889 | Implantable/insertable device, not otherwise classified | <1% | 760 | $88K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 648 | $86K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 16,999 | $84K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 715 | $80K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,309 | $80K |
| 97162 | <1% | 1,062 | $73K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 5,459 | $71K |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 396 | $71K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,201 | $69K |
| 76536 | <1% | 653 | $66K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 4,404 | $62K |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,587 | $62K |
| 83880 | <1% | 4,417 | $62K | |
| 74018 | <1% | 2,444 | $61K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 586 | $60K |
| 29581 | <1% | 390 | $60K | |
| 97597 | <1% | 871 | $58K | |
| 72141 | <1% | 307 | $54K | |
| 81025 | <1% | 6,386 | $52K | |
| 64493 | <1% | 85 | $48K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 4,398 | $47K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 24,558 | $46K |
| 87040 | <1% | 6,980 | $43K | |
| 73221 | <1% | 246 | $39K | |
| 71250 | <1% | 704 | $39K | |
| 80061 | Lipid panel | <1% | 9,156 | $36K |
| 72100 | <1% | 1,898 | $36K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 4,771 | $36K |
| 76642 | <1% | 349 | $35K | |
| 64635 | <1% | 77 | $35K | |
| S0028 | Injection, famotidine, 20 mg | <1% | 741 | $34K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 10,090 | $33K |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 978 | $33K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,399 | $32K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 1,032 | $32K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 17,293 | $32K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 336 | $32K |
| 73130 | <1% | 1,724 | $31K | |
| 73630 | <1% | 1,987 | $29K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 993 | $27K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,531 | $26K |
| 96367 | <1% | 410 | $26K | |
| 84439 | <1% | 5,359 | $26K | |
| 82607 | <1% | 6,053 | $25K | |
| 71045 | Radiologic examination, chest; single view | <1% | 8,163 | $24K |
| 87653 | <1% | 1,445 | $24K | |
| 73030 | <1% | 1,243 | $24K | |
| 73610 | <1% | 1,223 | $24K | |
| 73562 | <1% | 1,582 | $23K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 2,869 | $22K |
| 84484 | <1% | 15,745 | $22K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 3,947 | $22K |
| 86803 | <1% | 2,783 | $21K | |
| 85027 | <1% | 8,421 | $20K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 6,903 | $19K |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | <1% | 865 | $18K |
| 93246 | <1% | 479 | $18K | |
| 62321 | <1% | 29 | $18K | |
| 76775 | <1% | 183 | $17K | |
| 71271 | <1% | 157 | $16K | |
| 84702 | <1% | 2,189 | $16K | |
| 70486 | <1% | 202 | $15K | |
| 87088 | <1% | 5,543 | $15K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 13,627 | $15K |
| 94729 | <1% | 461 | $13K | |
| 82728 | <1% | 3,326 | $13K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,721 | $13K |
| 87070 | <1% | 2,103 | $13K | |
| 86850 | <1% | 3,180 | $13K | |
| 90715 | <1% | 857 | $12K | |
| 80329 | <1% | 1,599 | $12K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 1,444 | $12K |
| 0001A | <1% | 578 | $12K | |
| 87077 | <1% | 5,321 | $11K | |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 882 | $11K |
| 64494 | <1% | 57 | $11K | |
| 82950 | <1% | 1,601 | $11K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 474 | $10K |
| 86140 | <1% | 3,562 | $10K | |
| 83605 | <1% | 6,132 | $10K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,857 | $10K |
| 82565 | <1% | 1,653 | $10K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,782 | $10K |
| 73110 | <1% | 508 | $10K | |
| 76830 | Ultrasound, transvaginal | <1% | 137 | $10K |
| 96376 | <1% | 4,734 | $10K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 9,213 | $9K |
| 95806 | <1% | 13 | $9K | |
| 86901 | <1% | 3,077 | $9K | |
| 80143 | <1% | 1,572 | $9K | |
| 97035 | <1% | 217 | $8K | |
| 94726 | <1% | 325 | $8K | |
| 85379 | <1% | 1,897 | $8K | |
| 0002A | <1% | 255 | $8K | |
| 85610 | <1% | 6,501 | $8K | |
| 81003 | <1% | 4,822 | $7K | |
| 80055 | <1% | 999 | $7K | |
| 87186 | <1% | 4,414 | $7K | |
| 84112 | <1% | 331 | $6K | |
| 59025 | Fetal non-stress test | <1% | 36 | $6K |
| 82140 | <1% | 2,710 | $6K | |
| 83735 | <1% | 7,950 | $6K | |
| 76770 | <1% | 52 | $6K | |
| 83540 | <1% | 3,634 | $5K | |
| 83550 | <1% | 1,928 | $5K | |
| 73502 | <1% | 468 | $5K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 11,936 | $5K |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 514 | $5K |
| 83970 | <1% | 340 | $5K | |
| 93922 | <1% | 62 | $5K | |
| 82746 | <1% | 1,637 | $5K | |
| 82105 | <1% | 537 | $5K | |
| 12001 | <1% | 25 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 19,434 | $4K |
| 85652 | <1% | 3,798 | $4K | |
| 80076 | <1% | 1,259 | $4K | |
| 62323 | <1% | 18 | $4K | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 1,183 | $4K |
| 84481 | <1% | 564 | $4K | |
| 82570 | <1% | 2,512 | $4K | |
| 86592 | <1% | 1,180 | $4K | |
| 83615 | <1% | 3,066 | $4K | |
| 80320 | <1% | 1,210 | $4K | |
| 70496 | <1% | 27 | $4K | |
| 84550 | <1% | 2,036 | $4K | |
| 87015 | <1% | 753 | $4K | |
| 84156 | <1% | 1,342 | $4K | |
| 83690 | <1% | 13,050 | $4K | |
| 84145 | <1% | 355 | $4K | |
| 84703 | <1% | 4,125 | $4K | |
| 86900 | <1% | 3,190 | $4K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 14 | $3K |
| 87522 | Neg quan hep c or qual rna | <1% | 243 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 9,799 | $3K |
| 94010 | <1% | 93 | $3K | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 45 | $3K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 184 | $3K |
| 87340 | <1% | 1,480 | $3K | |
| 73080 | <1% | 100 | $3K | |
| 70491 | <1% | 29 | $3K | |
| 84403 | <1% | 262 | $3K | |
| 87081 | <1% | 834 | $3K | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 26 | $3K |
| 95886 | <1% | 23 | $3K | |
| 97166 | <1% | 55 | $3K | |
| Q9950 | Injection, sulfur hexafluoride lipid microspheres, per ml | <1% | 29 | $3K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 54 | $2K |
| 10060 | <1% | 12 | $2K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,081 | $2K |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 269 | $2K |
| C1729 | Catheter, drainage | <1% | 375 | $2K |
| 85730 | <1% | 2,108 | $2K | |
| 84100 | <1% | 2,859 | $2K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 783 | $2K |
| S0077 | Injection, clindamycin phosphate, 300 mg | <1% | 166 | $2K |
| 96523 | <1% | 29 | $2K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 29 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13,340 | $2K |
| 70498 | <1% | 40 | $2K | |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 33 | $2K |
| 43450 | <1% | 29 | $2K | |
| 74022 | <1% | 162 | $2K | |
| 73590 | <1% | 236 | $2K | |
| 84153 | <1% | 225 | $2K | |
| 82043 | <1% | 1,515 | $2K | |
| 80164 | <1% | 331 | $2K | |
| 93880 | <1% | 13 | $2K | |
| 93225 | <1% | 39 | $2K | |
| 97014 | <1% | 102 | $2K | |
| 88312 | <1% | 1,721 | $1K | |
| 94375 | <1% | 37 | $1K | |
| 82803 | <1% | 1,290 | $1K | |
| 86141 | <1% | 723 | $1K | |
| 94060 | <1% | 49 | $1K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 15 | $1K |
| 99152 | <1% | 499 | $1K | |
| 76000 | <1% | 152 | $1K | |
| 87205 | <1% | 1,789 | $1K | |
| 84466 | <1% | 974 | $1K | |
| 29125 | <1% | 15 | $1K | |
| 97163 | <1% | 61 | $1K | |
| 80179 | <1% | 1,519 | $1K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 69 | $1K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 1,364 | $1K |
| 82533 | <1% | 465 | $1K | |
| 77002 | <1% | 13 | $1K | |
| 82731 | <1% | 17 | $1K | |
| 86762 | <1% | 672 | $1K | |
| 64636 | <1% | 14 | $1K | |
| 93242 | <1% | 25 | $998.10 | |
| 36591 | <1% | 160 | $800.53 | |
| 87807 | <1% | 584 | $795.16 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 928 | $752.20 |
| 73090 | <1% | 100 | $724.18 | |
| 86038 | <1% | 160 | $716.03 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 14 | $699.62 |
| 71101 | <1% | 66 | $664.36 | |
| 93226 | <1% | 39 | $653.31 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 5,102 | $604.14 |
| 80074 | <1% | 63 | $598.29 | |
| 94762 | <1% | 103 | $585.87 | |
| G0379 | Direct admission of patient for hospital observation care | <1% | 16 | $583.94 |
| 86704 | <1% | 175 | $568.61 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 211 | $557.27 |
| 84681 | <1% | 141 | $521.31 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,952 | $510.05 |
| 84146 | <1% | 53 | $505.58 | |
| 82272 | <1% | 70 | $486.91 | |
| 88300 | <1% | 691 | $467.04 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,227 | $435.51 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,509 | $415.00 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 670 | $406.72 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 4,886 | $388.42 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 203 | $384.40 |
| 82550 | <1% | 326 | $371.35 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 3,035 | $306.73 |
| 72050 | <1% | 20 | $291.44 | |
| 86376 | <1% | 27 | $285.38 | |
| 88304 | <1% | 846 | $282.06 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 978 | $280.93 |
| 87147 | <1% | 307 | $279.37 | |
| 88307 | <1% | 15 | $244.98 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 4,230 | $237.84 |
| 97167 | <1% | 14 | $234.22 | |
| 86706 | <1% | 73 | $225.85 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,311 | $216.40 |
| 94664 | <1% | 233 | $209.56 | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 919 | $205.36 |
| 82977 | <1% | 77 | $202.19 | |
| 86800 | <1% | 24 | $188.66 | |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 92 | $187.93 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 3,258 | $186.41 |
| 85045 | <1% | 215 | $173.78 | |
| 82248 | <1% | 75 | $156.24 | |
| 83001 | <1% | 15 | $152.54 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 659 | $149.82 |
| J2704 | Injection, propofol, 10 mg | <1% | 12,799 | $141.62 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 1,921 | $141.50 |
| 86308 | <1% | 13 | $134.29 | |
| 81050 | <1% | 56 | $128.69 | |
| 83993 | <1% | 12 | $124.04 | |
| 36600 | <1% | 35 | $119.00 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 285 | $118.38 |
| 87449 | <1% | 25 | $110.82 | |
| 86430 | <1% | 58 | $101.80 | |
| 88302 | <1% | 52 | $99.36 | |
| 87210 | <1% | 108 | $84.97 | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 895 | $80.75 |
| 83721 | <1% | 15 | $77.97 | |
| 85018 | <1% | 50 | $68.68 | |
| 86003 | <1% | 18 | $66.67 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 992 | $57.47 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | <1% | 27 | $56.29 |
| 72170 | <1% | 29 | $56.28 | |
| 80156 | <1% | 12 | $55.12 | |
| 82378 | <1% | 31 | $54.93 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,261 | $52.56 |
| 83002 | <1% | 13 | $51.47 | |
| 88342 | <1% | 195 | $47.48 | |
| 84402 | <1% | 12 | $45.71 | |
| 86708 | <1% | 18 | $43.65 | |
| 85007 | <1% | 98 | $41.50 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 476 | $41.15 |
| J1815 | Injection, insulin, per 5 units | <1% | 287 | $40.76 |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 534 | $35.29 |
| 82150 | <1% | 29 | $32.52 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 613 | $31.82 |
| 86431 | <1% | 13 | $31.72 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 262 | $31.64 |
| 84460 | <1% | 15 | $22.98 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 461 | $21.84 |
| 84450 | <1% | 15 | $17.88 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 97 | $12.50 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 502 | $11.87 |
| 88341 | <1% | 15 | $10.22 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 177 | $10.06 |
| 82009 | <1% | 76 | $9.94 | |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 114 | $8.21 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 112 | $6.23 |
| C1769 | Guide wire | <1% | 315 | $5.38 |
| 94760 | <1% | 865 | $4.79 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 36 | $3.29 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 16 | $2.04 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 1,596 | $1.52 |
| J1940 | Injection, furosemide, up to 20 mg | <1% | 25 | $0.91 |
| 94761 | <1% | 1,189 | $0.43 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 69 | $0.17 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 950 | $0.00 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | 0% | 1,017 | $0.00 |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | 0% | 23 | $0.00 |
| 96417 | 0% | 19 | $0.00 | |
| A9537 | Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries | 0% | 15 | $0.00 |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 16 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 14 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 38 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 12 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 27 | $0.00 |
| A9270 | Non-covered item or service | 0% | 782 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 160 | $0.00 |
| J2471 | Injection, pantoprazole (hikma), not therapeutically equivalent to j2470, 40 mg | 0% | 18 | $0.00 |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | 0% | 71 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 19 | $0.00 |
| 96368 | 0% | 42 | $0.00 | |
| V2632 | Posterior chamber intraocular lens | 0% | 108 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 49 | $0.00 |
| A9500 | Technetium tc-99m sestamibi, diagnostic, per study dose | 0% | 13 | $0.00 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | 0% | 26 | $0.00 |
| 84132 | 0% | 15 | $0.00 | |
| 74019 | 0% | 12 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHILTON, SHANE (EVP/CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.